Company intelligence / Profile preview
Sanaregen Vision Therapeutics
- Ownership
- Private
- Development stage
- Phase 3
Overview
Sanaregen Vision Therapeutics develops affordable and accessible regenerative therapies aimed at restoring vision in patients with debilitating retinal diseases. Their pipeline targets drusen-related conditions such as Familial Drusen and advanced Geographic Atrophy. The company leverages over a century of combined expertise in neuroscience, regulatory affairs, patient advocacy, and retinal research to address unmet needs in ophthalmology. Clinical results are not yet published; the company appears focused on preclinical development through 2027.[1]
- Therapeutic areas
- Rare DiseasesOphthalmology
- Modalities
- Cell-based therapiesregenerative medicine[1]
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Sanaregen Vision Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanaregen Vision Therapeutics.